Novartis International AG / Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers . Processed and transmitted by West Corporation.
The issuer is solely responsible for the content of this announcement.
The issuer is solely responsible for the content of this announcement.
* In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of remission still not reached[1]
* The longer follow-up from the JULIET study in patients with r/r DLBCL reported 64% relapse-free probability and a 43% probability of overall survival at 18 months, with median duration of response still not reached[2]
* The safety profiles observed in both longer-term analyses remained consistent with previously reported results, with no emergence of new safety signals
* ASH presentations demonstrate the Novartis commitment to understanding the long-term potential of Kymriah in transforming the treatment of ALL and DLBCL
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.